Search results
Results from the WOW.Com Content Network
Endo is one of the companies named in lawsuits by the states of Ohio, [42] Missouri and Mississippi [43] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids. [44]
The law (TN Code 53-11-311) that prevents nurse practitioners (NPs) or physician assistants (PAs) from prescribing more than 16 milligrams of buprenorphine-naloxone daily (despite standard dosing ...
In response to the surging opioid prescription rates by health care providers that contributed to the opioid epidemic in the United States, US states began passing legislation to stifle high-risk prescribing practices (such as prescribing high doses of opioids or prescribing opioids long-term). These new laws fell primarily into one of the ...
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required, by section 202 of that Act, for substances to be placed in this schedule: The drug or other substance has a high potential for abuse.
Global consulting firm McKinsey & Company agreed Friday to pay $650 million to resolve criminal and civil investigations into the advice it provided to opioids manufacturer Purdue Pharma.
This is the list of Schedule I controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2] The drug or other substance has a high potential for abuse.
McKinsey & Co has agreed to pay $650 million to resolve a US Department of Justice investigation into the consulting firm’s work advising opioid manufacturer OxyContin maker Purdue Pharma on how ...
Titan's principal asset is Probuphine, [5] [6] a slow-release implant formulation of buprenorphine [7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. [8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. [6]